Mesenchymal stem cell-derived exosomes improved septic lung injury by reducing excessive NETs formation and alleviating inflammatory response.

To illustrate the potential of mesenchymal stem cell-derived exosomes (MSC-Exos) in mitigating septic lung injury by reducing the excessive formation of neutrophil extracellular traps (NETs), a mouse model of septic lung injury was induced through cecal ligation and puncture (CLP). The mice received intraperitoneal injections of MSC-Exos. Post injection, pathological alterations of the lung tissue were evaluated through HE staining, and the levels of inflammatory markers in each mouse group at various time points were assessed using ELISA kits.

Biomarkers.

Background: Cognitively unimpaired (CU) older adults with abnormal levels of β-amyloid (Aβ) deposition are considered in the preclinical stage of Alzheimer's disease (AD) and, when combined with the subjective cognitive decline (SCD), are proposed as the stage 2 AD in the NIA-AA framework. Here, we aim to investigate whether neuropathologic deterioration increases in early stages, particularly in stage 2 AD.

Method: We included 341 CU participants over 50 years of age from the Sino Longitudinal Study on Cognitive Decline (SILCODE) study.

Biomarkers.

Background: The thresholds of plasma β-amyloid(Aβ)/Aβ and phosphorylated Tau (p-Tau) to detect Alzheimer's disease (AD) pathophysiology in Chinese community older adults have not been well established. Besides, it is still unclear about the role of astrocyte reactivity in Aβ plaque deposition, tau tangle aggregation, and neurodegeneration in AD.

Method: In this study, we analyzed plasma Aβ/Aβ, p-Tau, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) using the Simoa platform in 470 Chinese older participants.

Drug Development.

Background: Reducing fibrous aggregates of protein tau is a possible strategy for halting progression of Alzheimer's disease (AD). Previously we found that in vitro the D-peptide D-TLKIVWC fragments tau fibrils from AD brains (AD-tau) into benign segments, whereas its six-residue analog D-TLKIVW cannot. However, the underlying fragmentation mechanism remains unknown, preventing the further development of this type of drug candidate for AD.

[Research progress on prognostic prediction models for patients undergoing extracorporeal membrane oxygenation].

Extracorporeal membrane oxygenation (ECMO), as a critical life support technology, has played a significant role in treating patients with refractory respiratory and circulatory failure. In recent years, with the advancements in medical technology, the scope of application of ECMO has been expanding, especially in the fields of acute respiratory distress syndrome, cardiogenic shock and other important roles. However, its high costs, complex operation, and associated risks of complications remain challenges in clinical practice.